Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Oct;53(10):844-54.
doi: 10.1007/s00262-004-0540-x. Epub 2004 Jun 10.

Escape from immunotherapy: possible mechanisms that influence tumor regression/progression

Affiliations
Review

Escape from immunotherapy: possible mechanisms that influence tumor regression/progression

Murrium Ahmad et al. Cancer Immunol Immunother. 2004 Oct.

Abstract

Tumor escape is one major obstacle that has to be addressed prior to designing and delivering successful immunotherapy. There is compelling evidence to support the notion that immunogenic tumors, in murine models and cancer patients, can be rejected by the immune system under optimum conditions for activating adaptive and nonadaptive antitumor immune responses. Despite this capability, a large number of tumors continue to grow and evade recognition and/or destruction by the immune system. The limited success in current immunotherapeutic strategies may be due to a variety of reasons: failure of effector cells to compete with the growing tumor burden, production of humoral factors by tumors that locally block cytotoxicity, antigen/MHC loss, T-cell dysfunction, production of suppressor T cells-to name but a few causes for therapeutic ineffectiveness for the particular malignancy being treated. To optimize immunotherapy strategies, correction of immune-activating signals, eradication of inhibitory factors, and the evasion from newly developed immunoresistant tumor phenotypes need to be simultaneously considered.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Summary of the processes of activation and suppression during tumor progression

Similar articles

Cited by

References

    1. Jakobisiak M, Lasek W, Golab J. Natural mechanisms protecting against cancer. Immunol Lett. 2003;90(2–3):103–22. - PubMed
    1. Speiser Cancer Immunol. 2003;3:12.
    1. Romero Pigment Cell Res. 2003;16:588. doi: 10.1034/j.1600-0749.2003.08353.x. - DOI
    1. Jager E, Jager D, Knuth A (2000) CTL-defined cancer vaccines in melanoma and other epithelial cancer. In: Stern PL, Beverely PCL, Carroll MW (eds) Cancer vaccines and immunotherapy. Cambridge University Press, Cambridge, pp 207
    1. Kaufmann HL, Schlorn J (2000) Vaccines in colon cancer. In: Stern PL, Beverely PCL, Carroll MW (eds) Cancer Vaccines and Immunotherapy. Cambridge University Press, Cambridge, p 107

MeSH terms